SMO ClinPlusLTD Past Earnings Performance
Past criteria checks 4/6
SMO ClinPlusLTD has been growing earnings at an average annual rate of 32.6%, while the Life Sciences industry saw earnings growing at 21.5% annually. Revenues have been growing at an average rate of 22.9% per year. SMO ClinPlusLTD's return on equity is 11.9%, and it has net margins of 16.8%.
Key information
32.6%
Earnings growth rate
23.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 22.9% |
| Return on equity | 11.9% |
| Net Margin | 16.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SMO ClinPlusLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 787 | 132 | 53 | 37 |
| 31 Dec 23 | 760 | 135 | 50 | 35 |
| 30 Sep 23 | 729 | 135 | 54 | 34 |
| 30 Jun 23 | 690 | 115 | 54 | 34 |
| 31 Mar 23 | 638 | 94 | 55 | 33 |
| 31 Dec 22 | 586 | 72 | 56 | 32 |
| 30 Sep 22 | 542 | 52 | 76 | 45 |
| 30 Jun 22 | 523 | 50 | 49 | 26 |
| 31 Mar 22 | 528 | 58 | 53 | 29 |
| 31 Dec 21 | 503 | 58 | 40 | 21 |
| 30 Sep 21 | 472 | 58 | 44 | 15 |
| 30 Jun 21 | 421 | 53 | 38 | 17 |
| 31 Mar 21 | 373 | 46 | 44 | 15 |
| 31 Dec 20 | 335 | 35 | 44 | 15 |
| 31 Dec 19 | 304 | 52 | 24 | 16 |
| 31 Dec 18 | 193 | 30 | 17 | 12 |
| 30 Sep 18 | 172 | 29 | 12 | 11 |
| 30 Jun 18 | 147 | 26 | 16 | 5 |
| 31 Mar 18 | 132 | 23 | 16 | 3 |
| 31 Dec 17 | 116 | 20 | 11 | 5 |
| 30 Sep 17 | 98 | 14 | 10 | 3 |
| 30 Jun 17 | 80 | 9 | 10 | 1 |
| 31 Mar 17 | 72 | 8 | 9 | 0 |
| 31 Dec 16 | 63 | 8 | 8 | 0 |
| 31 Dec 15 | 42 | -14 | 24 | 0 |
Quality Earnings: 301257 has a high level of non-cash earnings.
Growing Profit Margin: 301257's current net profit margins (16.8%) are higher than last year (14.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301257's earnings have grown significantly by 32.6% per year over the past 5 years.
Accelerating Growth: 301257's earnings growth over the past year (41.1%) exceeds its 5-year average (32.6% per year).
Earnings vs Industry: 301257 earnings growth over the past year (41.1%) exceeded the Life Sciences industry 0.9%.
Return on Equity
High ROE: 301257's Return on Equity (11.9%) is considered low.